Facial Radiation Therapy and Fillers: What to Assess First

Some patients arrive at the orofacial harmonization (HOF) clinic with a history that changes the routine: they have already been through cancer treatment of the head and neck and now want to regain self-esteem, contour, or symmetry. The wish is legitimate, and the approach has to be different. Tissue that has received radiation therapy does not behave like untouched tissue, and the risk of complications with injectables changes. This guide organizes what to assess, whom to talk to, and how to document, at a review level. Indication, timing, and technique are the decision of the qualified professional, in dialogue with the oncology team, according to the rules of their professional council.

What does radiation therapy do to facial tissue?

Radiation therapy uses ionizing radiation to destroy tumor cells. The effect also reaches normal tissue in the irradiated area, with acute effects (during and shortly after treatment) and late effects (months to years later). In general terms, the following are described:

1. Skin changes: dryness, color change, atrophy, telangiectasias, and, in some cases, fibrosis.
2. Fibrosis of subcutaneous tissue and muscles: hardening, loss of elasticity and mobility.
3. Altered blood supply: reduced caliber and density of small vessels, compromising nutrition and healing.
4. Chronic swelling and lymphatic changes: poor drainage, with persistent swelling in some areas.
5. Changes to the salivary glands and mucosa, when the mouth is in the field.
6. Effects on bone, at higher doses, with a risk of healing problems and infection.

These changes are late and progressive, and irradiated tissue tends to remain different over the years. That is why the fact that treatment ended long ago does not guarantee the area is "normal".

Why does this change the risk of injectables?

The safety of fillers and biostimulators depends on tissue with good blood supply, good healing capacity, and predictable anatomy. Irradiated tissue has exactly these characteristics altered, which raises concerns:

The aesthetic literature on this scenario is limited and largely made up of case reports and small series. That reinforces caution. See the reasoning on how to read the evidence in levels of evidence in HOF.

Whom should you talk to before any decision?

The cancer patient has a team: oncologist, radiation oncologist, head and neck surgeon, speech therapist, dentist, psychologist. A joint assessment is the safety standard.

1. Ask the patient's permission to contact the team and access relevant information.
2. Obtain written clearance from the responsible physician, with information on the status of the disease and the tissue.
3. Understand the irradiated field: area, dose, and date, when available.
4. Know the status of the disease: remission, follow-up, risk of recurrence.
5. Know about other ongoing treatments: chemotherapy, immunotherapy, medications that affect coagulation and immunity.
6. Discuss the goal: what the patient wants, and whether it makes sense from a clinical standpoint.

Is there any area that may be different?

The irradiated field does not always cover the entire face. Regions outside the field have a risk profile closer to usual, but assessing the overall context is still necessary. Points to consider:

• Radiation field and borders: confirm with the team which regions are inside.
• Associated surgery: scars, flaps, and reconstructions change anatomy and blood supply.
• Lymphedema: may require specific management and change the response to any procedure.
• Teeth and jaw: if radiation involved the oral region, there are specific dental precautions.

When in doubt, the principle is not to treat what you do not know. See the broader reasoning in general contraindications in HOF and medical history in HOF.

What should you tell the patient?

The cancer patient carries a heavy history and, often, an expectation of getting their former appearance back. The conversation calls for warmth and candor. Refusing the procedure without explaining is frustrating, and promising too much is dangerous.

Giving time for the decision, without pressure over dates or promotions, is part of good practice. See the importance of a welcoming approach in nonviolent communication in the HOF consultation.

What if the plan goes ahead?

If, after assessment and clearance, the professional decides to proceed, some precautions are expected:

1. Start with a conservative approach, in a small area and with the lowest volume that meets the goal.
2. Assess the response before expanding, with a scheduled follow-up.
3. Have an even more detailed complication plan, including availability of hyaluronidase when using hyaluronic acid and a rapid referral pathway. See clinic complication SOP.
4. Stay in contact with the oncology team during follow-up.
5. Document with photos the condition of the skin before and its evolution.
6. Avoid combining several procedures in the same session.

What should you not do?

• Treat without information about the irradiated field and the status of the disease.
• Promise a return to the former appearance.
• Perform extensive procedures in the first session.
• Ignore warning signs, such as pain, pallor, color change, or a wound that does not close.
• Inject into an area with a wound, infection, or suspicious lesion.
• Treat lesions that could be a recurrence without medical assessment. Any new nodule in a cancer patient needs investigation.
• Publicize the case without express permission. See ethical portfolio in HOF.

What should you document?

The patient record should be especially complete: reported diagnosis, treatment received, irradiated field, contact with the team, written clearance, skin exam, photos, risk discussion, decision made, and follow-up. The informed consent needs to mention that irradiated tissue carries a higher risk and that complications may be harder to treat. If the patient refuses contact with the team, document it and assess whether it is safe to proceed.

The main point

Prior radiation therapy transforms the tissue and the risk. The patient deserves warmth, information, and a decision shared with those who follow the disease. In many cases, the best path is to wait, preserve, and move slowly, or simply not treat the area. When treating, the plan is more cautious, the consent is more detailed, and the follow-up is closer.